Abivax Aktie - ABVX

Professionelle Tools für Privatanleger.

Premium

Current Price

6,94

Gebot

6,80

Fragen

7,50

Volumen

890.079

6,94 Tagesbereich 7,28

5,62 52-Wochen-Bereich 15,42

Marktkapitalisierung

436,726M

Handelsende

7,40

Handelsbeginn

7,28

Letzte Trade

547

6.94

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

32.504

Ausgegebene Aktien

62.928.818

Dividendenrendite

Kurs-Gewinn-Verhältnis

-2,96

Gewinn pro Aktie (EPS)

-2,35

Erlöse

4,62M

Nettogewinn

-147,74M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.abivax.com

Hauptsitz

Paris, Paris, Fra

Gegründet

Abivax is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ABVX. The last closing price for Abivax was 7,40 €. Over the last year, Abivax shares have traded in a share price range of 5,62 € to 15,42 €.

Abivax currently has 62.928.818 shares in issue. The market capitalisation of Abivax is 465,67 € million. Abivax has a price to earnings ratio (PE ratio) of -2.96.

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist...

Abivax Publishes 2025 Financial Calendar

Abivax Publishes 2025 Financial Calendar PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext...

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s...

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod...

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024...

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET –...

Abivax presents third quarter 2024 key financial information

Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax...

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its...

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.37	-5.06155950752	7.31	7.68	6.94	35279	7.34262538	DE
4	1.05	17.8268251273	5.89	7.68	5.62	43216	6.69590153	DE
12	-0.91	-11.5923566879	7.85	8.15	5.62	32504	6.63951392	DE
26	-3.48	-33.3973128599	10.42	11.98	5.62	25828	7.75989203	DE
52	-6.56	-48.5925925926	13.5	15.42	5.62	25011	10.16271304	DE
156	-12.24	-63.8164754953	19.18	26.25	5.6	33186	11.37527782	DE
260	-6.72	-49.1947291362	13.66	39	5.6	32964	16.2198867	DE

ABVX - Frequently Asked Questions (FAQ)

What is the current Abivax share price?

The current share price of Abivax is 6,94 €

How many Abivax shares are in issue?

Abivax has 62.928.818 shares in issue

What is the market cap of Abivax?

The market capitalisation of Abivax is EUR 465,67M

What is the 1 year trading range for Abivax share price?

Abivax has traded in the range of 5,62 € to 15,42 € during the past year

What is the PE ratio of Abivax?

The price to earnings ratio of Abivax is -2,96

What is the cash to sales ratio of Abivax?

The cash to sales ratio of Abivax is 94,55

What is the reporting currency for Abivax?

Abivax reports financial results in EUR

What is the latest annual turnover for Abivax?

The latest annual turnover of Abivax is EUR 4,62M

What is the latest annual profit for Abivax?

The latest annual profit of Abivax is EUR -147,74M

What is the registered address of Abivax?

The registered address for Abivax is 7-11 BOULEVARD HAUSSMANN, PARIS, PARIS, 75009

What is the Abivax website address?

The website address for Abivax is www.abivax.com

Which industry sector does Abivax operate in?

Abivax operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ALADOAdomos	0,59 € (180,95%)	162,85k
ALCYBCybergun	0,0002 € (100,00%)	24,87M
DMSBSDiagnostic Medical Systems	0,008 € (77,78%)	50k
ALAMAAMA Corporation PLC	0,233 € (29,81%)	847,73k
LUDSLucibel DS	0,0015 € (25,00%)	13,29k
NEGDSNetmedia Group DS	0,0001 € (-50,00%)	698
ALPCVCerinnov Group	0,618 € (-33,55%)	230,29k
ALKALKALRAY SA	0,641 € (-27,98%)	530,33k
BPOSTBpost SA NV	1,522 € (-26,83%)	6,5M
FRVIAForvia SE	8,442 € (-22,62%)	6,19M
ATOAtos SE	0,0032 € (0,00%)	472,41M
BCPBanco Comercial Portugues SA	0,5366 € (-4,89%)	135,45M
BIOSBiosenic	0,0029 € (-6,45%)	37,45M
ALALOAcheterLouerFR	0,0073 € (0,00%)	36,35M
ALVERVergnet	0,0004 € (0,00%)	33,19M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Abivax (ABVX) Börsenkurse

Abivax (ABVX)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Abivax

ABVX Neueste Nachrichten

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

ABVX - Frequently Asked Questions (FAQ)

Beweger

ABVX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen